Frazier Elisabeth A, Gracious Barbara, Arnold L Eugene, Failla Mark, Chitchumroonchokchai Chureeporn, Habash Diane, Fristad Mary A
Department of Psychiatry, Department of Human Nutrition, The Ohio State University , Columbus, Ohio.
J Child Adolesc Psychopharmacol. 2013 Oct;23(8):558-67. doi: 10.1089/cap.2012.0098.
The purpose of this study was to report the safety, tolerability, and serum micronutrient concentrations and their correlations with mood changes from an 8 week pilot feasibility study of a 36 ingredient multinutrient supplement, EMPowerplus (EMP+), for pediatric bipolar spectrum disorders (BPSD).
Ten children ages 6-12 received EMP+ escalating from one to four capsules t.i.d., with four children increased to the maximum suggested dose, five capsules t.i.d. Outcome measures were micronutrient concentrations in serum and red blood cells, vital signs, body mass index (BMI), dietary intake (Food Frequency Questionnaire and 24 hour dietary recall interview), and mood and global functioning ratings.
Seven children (70%) completed the study. Three (30%) terminated early for tolerability and compliance issues. Adverse effects were mild and transient, and chiefly consisted of initial insomnia or gastrointestinal (GI) upset. No differences occurred in BMI (p = 0.310) or waist-hip ratio (WHR; p = 0.674) pre- to postsupplementation. Four of the tested serum vitamin concentrations increased from pre- to postsupplementation: vitamin A-retinol, vitamin B6, vitamin E-α-tocopherol; and folate (all p<0.05). The increase in serum 25-OH vitamin D approached significance (p = 0.063). No differences were found in dietary intake pre- to postsupplementation, suggesting that blood nutrient level increases were caused by EMP+.
In this open prospective study, short-term use of EMP+ in children with BPSD appeared safe and well-tolerated, with a side effect profile preferable to first-line psychotropic drugs for pediatric bipolar spectrum disorders. A double-blind, randomized clinical trial is feasible, appears safe, and is warranted by open-label clinical outcomes and plausible mechanisms of action, combined with documentation of increased serum concentrations of specific micronutrients.
本研究旨在报告一项为期8周的试点可行性研究的安全性、耐受性、血清微量营养素浓度及其与情绪变化的相关性。该研究针对儿童双相情感障碍谱系障碍(BPSD)使用了一种含有36种成分的多种营养素补充剂Empowerplus(EMP+)。
10名6至12岁的儿童服用EMP+,剂量从每日三次、每次1粒胶囊逐渐增加至每日三次、每次4粒胶囊,其中4名儿童增加至最大建议剂量,即每日三次、每次5粒胶囊。观察指标包括血清和红细胞中的微量营养素浓度、生命体征、体重指数(BMI)、饮食摄入量(食物频率问卷和24小时饮食回顾访谈)以及情绪和整体功能评分。
7名儿童(70%)完成了研究。3名儿童(30%)因耐受性和依从性问题提前终止。不良反应轻微且短暂,主要包括最初的失眠或胃肠道不适。补充前后BMI(p = 0.310)或腰臀比(WHR;p = 0.674)无差异。补充后,所检测的4种血清维生素浓度升高:维生素A - 视黄醇、维生素B6、维生素E - α - 生育酚和叶酸(均p<0.05)。血清25 - OH维生素D的升高接近显著水平(p = 0.063)。补充前后饮食摄入量无差异,表明血液营养素水平的升高是由EMP+引起的。
在这项开放性前瞻性研究中,BPSD儿童短期使用EMP+似乎安全且耐受性良好,其副作用谱优于治疗儿童双相情感障碍谱系障碍的一线精神药物。双盲、随机临床试验是可行的,似乎也是安全的,并且基于开放性标签临床结果、合理的作用机制以及特定微量营养素血清浓度升高的记录,有必要进行该试验。